ES2170390T3 - Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c. - Google Patents

Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c.

Info

Publication number
ES2170390T3
ES2170390T3 ES97921288T ES97921288T ES2170390T3 ES 2170390 T3 ES2170390 T3 ES 2170390T3 ES 97921288 T ES97921288 T ES 97921288T ES 97921288 T ES97921288 T ES 97921288T ES 2170390 T3 ES2170390 T3 ES 2170390T3
Authority
ES
Spain
Prior art keywords
fluorenonas
protein
compounds
substituidas
alquiloxiamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97921288T
Other languages
English (en)
Inventor
Winton D Jones
Fred L Ciske
Robert J Dinerstein
Keith A Diekema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170390(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2170390T3 publication Critical patent/ES2170390T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/24—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN LA PRESENTE INVENCION SE DESCRIBEN CIERTAS FLUORENONAS SUSTITUIDAS POR ALQUILOXIAMINOS QUE INHIBEN LA PROTEINA C QUINASA, ASI COMO COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y METODOS DE USO DE ESTOS COMPUESTOS PARA CONTROLAR LA ACTIVIDAD DE LA PROTEINA C QUINASA EN MAMIFEROS, INCLUIDOS LOS SERES HUMANOS. DE MANERA ESPECIFICA, LOS PRESENTES COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ESTADOS DE DOLENCIAS NEOPLASICAS, TRASTORNOS ASOCIADOS A UN FLUJO SANGUINEO ANORMAL (INCLUIDAS LA HIPERTENSION, ISQUEMIA, ATEROSCLEROSIS, DEFICIENCIAS COAGULATIVAS) Y ENFERMEDADES INFLAMATORIAS (INCLUIDAS LAS INMUNODEFICIENCIAS, ASMA, FIBROSIS PULMONAR Y PSORIASIS).
ES97921288T 1996-05-30 1997-04-24 Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c. Expired - Lifetime ES2170390T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65558496A 1996-05-30 1996-05-30
US65553796A 1996-05-30 1996-05-30

Publications (1)

Publication Number Publication Date
ES2170390T3 true ES2170390T3 (es) 2002-08-01

Family

ID=27096988

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921288T Expired - Lifetime ES2170390T3 (es) 1996-05-30 1997-04-24 Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c.

Country Status (17)

Country Link
EP (1) EP0906268B1 (es)
JP (1) JP3897363B2 (es)
CN (1) CN1160309C (es)
AR (1) AR008375A1 (es)
AT (1) ATE209626T1 (es)
AU (1) AU737073B2 (es)
BR (1) BR9709406B1 (es)
CA (1) CA2257136C (es)
DE (1) DE69708629T2 (es)
DK (1) DK0906268T3 (es)
ES (1) ES2170390T3 (es)
HU (1) HUP9901621A3 (es)
IL (1) IL126873A (es)
NO (1) NO312457B1 (es)
NZ (1) NZ332597A (es)
PT (1) PT906268E (es)
WO (1) WO1997045397A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
DE19908504C2 (de) * 1999-02-26 2003-04-30 Boehringer Ingelheim Pharma Großtechnisches Verfahren zur Herstellung von Derivaten der Biphenyl-2-carbonsäure durch Verseifen eines (2-Oxazolinyl)-2-biphenyl-Derivats mit Salzsäure
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
CA2411924A1 (en) * 2000-08-18 2002-02-28 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
JP2013516500A (ja) * 2010-01-11 2013-05-13 ヒールオア・リミテッド 炎症性疾患および障害を治療するための方法
RU2444512C1 (ru) * 2010-10-18 2012-03-10 Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) Способ получения дигидрохлорида 2,7-бис-[2-(диэтиламино)этокси]-флуоренона-9
CN103204781B (zh) * 2013-03-14 2015-04-01 武汉大学 2,7–二取代芴酮衍生物及其制备方法与应用
CN109053435A (zh) * 2018-08-03 2018-12-21 上海华堇生物技术有限责任公司 2,3-二甲氧基苯甲酰氯的制备方法
CN115590964A (zh) * 2022-09-14 2023-01-13 苏州大学（Cn） 蛋白激酶c抑制剂在制备抗肿瘤转移药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33573A (en) * 1968-12-30 1973-10-25 Richardson Merrell Inc Bis-basic ethers and thioethers of fluorenone,fluorenol and fluorene
US5034384A (en) * 1990-08-01 1991-07-23 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem antibacterial agents

Also Published As

Publication number Publication date
NZ332597A (en) 2000-08-25
NO312457B1 (no) 2002-05-13
DE69708629D1 (de) 2002-01-10
HUP9901621A3 (en) 2002-01-28
CA2257136C (en) 2004-07-20
EP0906268A1 (en) 1999-04-07
EP0906268B1 (en) 2001-11-28
IL126873A0 (en) 1999-09-22
AU2736597A (en) 1998-01-05
DE69708629T2 (de) 2002-08-01
NO985577L (no) 1999-01-27
IL126873A (en) 2005-09-25
HK1019147A1 (en) 2000-01-14
DK0906268T3 (da) 2002-03-18
PT906268E (pt) 2002-05-31
JP3897363B2 (ja) 2007-03-22
JP2000511528A (ja) 2000-09-05
HUP9901621A2 (hu) 1999-08-30
NO985577D0 (no) 1998-11-27
AU737073B2 (en) 2001-08-09
BR9709406A (pt) 1999-08-10
AR008375A1 (es) 2000-01-19
ATE209626T1 (de) 2001-12-15
BR9709406B1 (pt) 2009-05-05
WO1997045397A1 (en) 1997-12-04
CN1160309C (zh) 2004-08-04
CN1220660A (zh) 1999-06-23
CA2257136A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
ES2170390T3 (es) Fluorenonas alquiloxiamino-substituidas y su uso como inhibidores de la proteina kinasa-c.
PT1254899E (pt) Derivados de piperazina e sua utilizacao como agentes anti-inflamatorios
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
SV2002000289A (es) Antagonistas del factor liberador de la corticotropina ref. pc10759/20117/bb
BR9713462A (pt) Métodos para produção de compostos carotenóides e óleos especiais em sementes de plantas.
CL2004000376A1 (es) Compuestos derivados de fenil propil amidas n-(aminoiminometil o aminometil) susttiuidas; compuestos intermediarios; composicion farmaceutica; y su uso para tratar un efecto patologico de la trombina, como trastornos tromboticos venosos o arteriales.
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
ECSP003590A (es) Compuestos calcioliticos
PA8514601A1 (es) Tratamiento de trastornos renales
UY28203A1 (es) Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ES2193424T3 (es) Aminas triciclicas farmaceuticamente activas.
DK0891326T3 (da) Nye D-vitaminanaloger
ES2162686T3 (es) Nuevos derivados carboxamidas ciclicos sustituidos por carboxi.
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
BR9704964A (pt) Uso de sulbutiamina para obter composições farmacêuticas úteis no tratamento de algumas pertubações psicomotoras e psico-intelectuais
AR011907A1 (es) UTILIZACIoN DEL ACIDO 4-(2,2-DIMETILPROPANOL)BUTANOICO (PIVAGABIN)PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE FORMAS DE ANSIEDADDEPRESIVA.
ECSP961724A (es) Nuevos derivados del acido hidroximico
MX9305151A (es) Metodo para el tratamiento de enfermedades de la piel.
SV1994000023A (es) Pirroles sustituidos ref. ran 4070/90

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 906268

Country of ref document: ES